Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Current Leases (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Current Leases for 5 consecutive years, with $667000.0 as the latest value for Q1 2026.

  • For Q1 2026, Current Leases rose 111.08% year-over-year to $667000.0; the TTM value through Mar 2026 reached $667000.0, up 111.08%, while the annual FY2025 figure was $648000.0, 29.34% up from the prior year.
  • Current Leases hit $667000.0 in Q1 2026 for Phathom Pharmaceuticals, up from $648000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $730000.0 in Q1 2024 and bottomed at $238000.0 in Q2 2025.
  • Average Current Leases over 5 years is $616352.9, with a median of $680000.0 recorded in 2024.
  • Year-over-year, Current Leases tumbled 66.94% in 2025 and then skyrocketed 111.08% in 2026.
  • Phathom Pharmaceuticals' Current Leases stood at $708000.0 in 2022, then increased by 2.54% to $726000.0 in 2023, then tumbled by 30.99% to $501000.0 in 2024, then grew by 29.34% to $648000.0 in 2025, then grew by 2.93% to $667000.0 in 2026.
  • According to Business Quant data, Current Leases over the past three periods came in at $667000.0, $648000.0, and $591000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.